Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07161414 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
A Phase 1 study of Advanced Solid Tumors, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 11
- Study locations
NCT07161414: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by AstraZeneca.
NCT07161414 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 40 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (80% lower). The trial reports 11 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07161414, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.
Primary Outcome
Bioavailability based on AUCtau at first SC dose will be determined.
Conditions Studied
Interventions
- DRUG IV Rilvegostomig
- DRUG Recombinant Human Hyaluronidase (rHu)
- DRUG SC Rilvegostomig
- DRUG SC rilvegostomig + rHu
Study Locations (11)
Other
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Barcelona
- Research Site - Madrid
- Research Site - Madrid
- Research Site - Newcastle upon Tyne
- Research Site - Sutton
North Carolina
- Research Site - Huntersville
Texas
- Research Site - San Antonio
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-11-25 |
| Est. Completion | 2029-07-24 |
| Phase | Phase 1 |
What NCT07161414 shows while recruiting
NCT07161414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which IV Rilvegostomig is the first listed.
NCT07161414 lists 11 locations in 4 states (Other, North Carolina, Texas).
Frequently Asked Questions
What is clinical trial NCT07161414 about?
NCT07161414 is a clinical study titled "A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy". The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standa...
What is the current status of trial NCT07161414?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-11-25. Estimated completion is 2029-07-24.
What conditions does trial NCT07161414 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT07161414?
The interventions under investigation include: IV Rilvegostomig (DRUG), Recombinant Human Hyaluronidase (rHu) (DRUG), SC Rilvegostomig (DRUG), SC rilvegostomig + rHu (DRUG).
Who is sponsoring clinical trial NCT07161414?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07161414 being conducted?
This trial has 11 study locations across North Carolina, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07161414's enrollment target sits among peer trials
40 110th of 144 higher than 34 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI